Merck’s decision to establish oncology as a standalone business unit is easy to describe and tempting to oversimplify. At ...

Gilead Sciences agreed to acquire Arcellx in a deal valued at approximately $7.8 billion in total, deepening its push into cell therapy for multiple myeloma.

In a conversation with Pharmaceutical Executive, Jay Bregman, CEO and co-founder of Andel, discusses the potential impact of the FDA's increased scrutiny on non-FDA approved GLP-1 products, ...

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

HHS Secretary Robert F. Kennedy Jr. reorganized senior leadership at the department to streamline management and advance the ...

In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims ...

In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary ...

On the heels of a Type A meeting with FDA’s Center for Biologics and Research (CBER), Moderna’s seasonal influenza vaccine ...

The broader Miami-Fort Lauderdale-West Palm Beach metro produced $533.7 billion in GDP in 2023, a nearly 9% year-over-year ...

What’s been overlooked is that the FDA already has the power to fix this. Without new legislation, pilot programs, or years ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...